
	Where results make sense

Topic: Lundbeck

Related Topics

Shire Pharmaceuticals

Citalopram

AstraZeneca

Abbott Laboratories

Amgen

Novartis

Genentech

List of pharmaceutical companies

List of genetic disorders

Turner syndrome

Verlan

Makati City

Elvis Presley

Music of the Philippines

Roald Dahl

In the News (Tue 1 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Pu at Lundbeck (Site not responding. Last check: 2007-11-03)
		Lundbeck Research USA, Inc. is a branch of the H. Lundbeck A/S, a global company headquartered in Denmark that is dedicated to developing pharmaceuticals for psychiatric and neurological disorders.
		Lundbeck gained the rights to the compound ketobemidon and developed into Ketogan®, which is still widely used as an acute pain reliever since its introduction in 1952.
		Lundbeck also dabbled in microbiology with the production of Neomycin®, a preparation for the treatment of wound infections, but that ended after a couple of decades since the outlook of developing new antibiotics were slim.
	www.bergen.org /ACADEMY/SeniorExp/2006/Pu.htm (1974 words)

	H.Lundbeck A/S - About us (Site not responding. Last check: 2007-11-03)
		Lundbeck's research activities concentrate on developing new and innovative pharmaceuticals for treating diseases of the central nervous system.
		Lundbeck India is preparing for the launch of its original research products for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, sleep disorders, anxiety and several other CNS diseases.
		Lundbeck India has forged close relationship with specialists in psychiatry and neurology and developed effective educational programmes that aim to improve the quality of life for the patients with CNS disorders and also for their families.
	www.timesjobs.com /lundbeck/about.html (257 words)

	Lundbeck (Site not responding. Last check: 2007-11-03)
		Lundbeck is a Danish based CNS pharmaceutical company with a strong and expanding presence in many parts of the world.
		Between 1965 and 1967 the Lundbeck Foundation was formed from the assets of the Group and the revenue received is used for humanitarian purposes such as medical research.
		Lundbeck is currently the market leader in depot ani-psychotic therapy and has researched and developed many of the world's leading antidepressants, including amitriptyline and nortriptyline.
	www.iol.ie /web/l/lundbeck (242 words)

	Lundbeck Login Page (Site not responding. Last check: 2007-11-03)
		Lundbeck research and development activity is concentrated on developing new and innovative pharmaceuticals for treating diseases of the central nervous system (CNS).
		Lundbeck is the only full-fledged pharmaceutical company in the world, solely devoted to the treatment of central nervous system disorders.
		Lundbeck India is fully committed to strive to the vision and mission of Lundbeck through the early introduction of original research drugs and also the innovative programs that have benefited patients and doctors elsewhere in the world.
	www.lundbeckindia.org (165 words)

	[No title]
		The Lundbeck Group has a turnover approaching £800m and Lundbeck UK is the largest subsidiary in the group with staff of over 260.
		Lundbeck then assigned a project manager from its HR department to work with Absoft on ESS, primarily to clarify requirements and undertake testing.
		Lundbeck’s mission is to improve the quality of life of those who suffer from psychiatric and neurological illness and believes this is best achieved through investment in knowledge, research, education and holistic attitudes to patient care.
	searchsap.techtarget.com /searchSAP/downloads/Lundbeck.doc (1045 words)

	Lundbeck - Wikipedia, the free encyclopedia
		Lundbeck A/S (KFX: LUN) (also known as Lundbeck) is a Danish international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.
		The company was founded by Hans Lundbeck in 1915, and was initially a trading company supplying a variety of goods to the Danish market, including machinery for manufacturing, aluminium foil, artificial sweeteners and photographic equipment.
		Lundbeck entered the pharmaceutical market in 1924, importing medicines and cosmetics from companies based in other European and American countries.
	en.wikipedia.org /wiki/Lundbeck (207 words)

	Lundbeck initiates phase I trial of Lu AA34893 for depression : Epilepsy.com
		Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of depression and anxiety disorders.
		For a number of years, Lundbeck has focused its research on characterizing the particularly favorable effect demonstrated by Cipralex in animals as well as in humans.
		"It is important for Lundbeck's research to discover new compounds that may improve the treatment and satisfy the unmet medical needs that currently exist in the treatment of depression and anxiety disorders.
	www.epilepsy.com /newsfeed/pr_1146490210.html (288 words)

	Pharmaceutical Technology - Lundbeck Pharmaceuticals Limited Seal Sands Pharmaceutical Manufacturing Plant, UK
		In April 2000, Lundbeck Pharmaceuticals Limited, the UK subsidiary of H. Lundbeck A/S of Denmark, awarded contracts for a new bulk pharmaceutical facility to be constructed at Seal Sands, Teesside, in North East England.
		Lundbeck's purification process of escitalopram, including chromatographic continuous step process performed with a Novasep simulated moving bed system, has been successfully approved by the FDA.
		Lundbeck already markets citalopram as a mixture of two enantiomers (enatiomers are optical isomers of a compound and in this case there are two, which are mirror images of one another).
	www.pharmaceutical-technology.com /projects/sealsands (888 words)

	PharmaTimes WorldNews\| Daily pharmaceutical news \| Lundbeck shares slip as profits slide (Site not responding. Last check: 2007-11-03)
		The decline in profit had been expected after Lundbeck warned of declining sales of the active pharmaceutical ingredient (API) for Lexapro (escitalopram oxalate) to US licensee Forest, mainly because of inventory overstocking in previous quarters.
		However, a pick-up in Lexapro sales reported by Forest in the first-half of this year could signal a recovery going forward, while there was great news for both companies after a US court upheld a patent on the drug and blocked the entry of a generic rival from Teva Pharmaceutical Industries.
		Sales of Cipralex (escitalopram oxalate) by Lundbeck were 856 million crowns in the second quarter, up 31%, while Alzheimer's disease drug Ebixa (memantine) climbed 27% to 337 million crowns.
	pharmatimes.com /news/9385-Lundbeck-financial-results.aspx?src=PTWeek (262 words)

	Lundbeck Research USA, Inc.
		Lundbeck is a global pharmaceutical company headquartered in Copenhagen, Denmark with over 5000 employees worldwide and subsidiaries in over 60 countries.
		Lundbeck is a growing company with several compounds in various stages of development for indications such as depression, psychosis, Alzheimer's disease and schizophrenia.
		In 1995, Lundbeck entered into a license and supply agreement with Forest Laboratories for the development and marketing of CelexaTM, the trademark brand name under which citalopram is marketed in the United States.
	www.biospace.com /company_profile.aspx?CompanyID=930720 (436 words)

	Pharmexa UK - H. Lundbeck
		Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.
		On April 15, 2000, Pharmexa entered into a research and development collaboration with H. Lundbeck for the use of Pharmexa’s AutoVac technology for the development of a therapeutic vaccine for treatment of neurodegenerative diseases in humans.
		In addition, H. Lundbeck will pay a down payment to Pharmexa and, depending on results obtained, total milestone payments of approximately DKK 150 million over the entire duration of the project.
	www.epimmune.com /site.asp?p=344 (176 words)

	Promising Lundbeck antidepressant goes into phase II clinical trials
		Danish pharmaceutical company H. Lundbeck is to enrol 400 patients into a phase II clinical study for its new antidepressant candidate drug Lu AA21004 by the end of Q3 2006.
		Lu AA21004 is the result of original development work by Lundbeck into a new chemical class of psychotropics, the bis-aryl-sulphanyl amines, the pharmacology of which is said to be markedly different from currently marketed antidepressants.
		Lundbeck has developed the bis-aryl-sulphanyl amines as a platform for molecular engineering to enable the design of different compounds with different pharmacological mechanisms, so that a range of products can be produced based on the same core molecular structure.
	www.investindk.com /visNyhed.asp?artikelID=15568 (313 words)

	Consumers International - Lundbeck
		Lundbeck has an overall code of conduct for medical representatives.
		Lundbeck states that it is focused on being responsible, and therefore '() each subsidiary's specific code of conduct for medical responsibility is developed locally in order to comply with all national sales and marketing rules and restrictions.'[3]
		No information was found the implementation mechanisms accompanying Lundbeck's country-specific codes of conduct for medical responsibility.
	www.consumersinternational.org /Templates/Internal.asp?NodeID=95392&int1stParentNodeID=89650&int2ndParentNodeID=95352&int3rdParentNodeID=95360 (156 words)

	:: invivodata - Lundbeck Chooses invivodata :: (Site not responding. Last check: 2007-11-03)
		Patients are being asked to record the quality and duration of their sleep cycles and also note how long it takes for them to fall asleep in their handheld electronic patient diary.
		Lundbeck is currently recruiting patients for the Phase III efficacy study at sites in Austria, Belgium, Canada, the Czech Republic, Denmark, Estonia, France, Finland, Germany, Italy, Norway, the Netherlands, Poland, Spain, Sweden, Switzerland, and the United Kingdom.
		Lundbeck can then use invivodata's powerful patient management tools to track the progress of study subjects and sites.
	www.invivodata.com /news_press/pr_Lundbeck.html (647 words)

	Lundbeck retains FY guidance as Q1 opg beats consensus UPDATE - Forbes.com (Site not responding. Last check: 2007-11-03)
		Lundbeck had previously seen 12 pct year-on-year growth in 2006 operating earnings from the 2.170 bln dkr posted in 2005, but lowered this markedly in February after its US partner, Forest Laboratories Inc, reduced its orders for escitalopram API in 2006.
		Lundbeck said first-quarter sales were driven by an increase in sales of the Cipralex anti-depressant and the Ebixa treatment of Alzheimers, which increased by 57 pct and 29 pct, respectively, from the year before.
		Lundbeck said the negative net financial income was due to, among other things, losses on the bond portfolio and on trading contracts.
	www.forbes.com /markets/feeds/afx/2006/05/09/afx2730651.html (633 words)

	Forbes.com: Scientists see no improvement in new Lundbeck drug (Site not responding. Last check: 2007-11-03)
		Lundbeck is pinning much of its future income to Cipralex succeeding its original blockbuster Cipramil which lost its European patent in 2002 and now faces cheap generic competition.
		Shares in Lundbeck dropped 3.2 percent to 107 crowns by 1000 GMT on a 0.8 percent higher Copenhagen bourse.
		The scientists studied trail reports from Lundbeck and the Swedish drug regulatory authority, consisting of a pooled analysis of 1,321 patients from one unpublished, one partly published and one published eight-week trial as well as a 24-week trial with 357 patients published as a poster.
	www.forbes.com /home_europe/newswire/2004/01/14/rtr1210205.html (494 words)

	Lundbeck launches Serdolect in Europe
		Lundbeck has launched its schizophrenia treatment Serdolect (sertindole) in Europe.
		Lundbeck head of drug development Anders Gersel Pedersen said: "We are very pleased that patients suffering from schizophrenia can now benefit from Serdolect.
		Lundbeck responded with an additional study of 5,000 patients to confirm the drug could be prescribed safely.
	www.allaboutmedicalsales.com /news/0106/Lundbeck_Serdolect_18.html (266 words)

	H. Lundbeck and Pharmexa Achieve Important Milestone in Research Collaboration : ArriveNet Press Releases : Health (Site not responding. Last check: 2007-11-03)
		In April 2000 Pharmexa entered into a 3-year research and developmentcollaboration with H. Lundbeck concerning the use of the AutoVaca technology on a certain protein target in the central nervous system to develop a treatment of Alzheimer's disease.
		Peter Hongaard Andersen, Divisional Director of Biological Research in H. Lundbeck said: "We have in the last few years seen indications that biotechnology-based drugs could be relevant in the treatment of psychiatric and neurological disorders, and here H. Lundbeck in the collaboration with Pharmexa has achieved a leading position.
		Soren Mouritsen, CEO of Pharmexa said: "We are very pleased with our partnership with H. Lundbeck, one of the worlds leading companies in the field of psychiatric and neurological disorders, and with the results achieved so far in the collaboration.
	press.arrivenet.com /health/article.php/328148.html (854 words)

	Lundbeck Clinical Trial Registry (Site not responding. Last check: 2007-11-03)
		This site (www.lundbecktrials.com) has been constructed by H. Lundbeck A/S (Lundbeck) and is intended to serve as a registry, with publicly available lists of Lundbeck-sponsored clinical confirmatory efficacy and safety trials, using the Lundbeck trial number as the unique trial identifier.
		For completed clinical trials with products marketed and actively promoted by Lundbeck, the results will be disclosed either within 1 year of commercial availability in the European Union, or within 1 year after trial completion, whichever is later.
		When it is necessary to inform investors, Lundbeck will first disclose clinical trial results of any one trial via a press release to the Stock Exchange before posting the trial results on the Lundbeck Clinical Trial Registry.
	www.lundbecktrials.com (285 words)

	BOARD M.I.T Delivers Speed, Simplicity and Cost-Effectiveness for Lundbeck
		Lundbeck business and R&D focus areas are psychiatry and neurology.
		Lundbeck has subsidiaries in 29 countries and partner alliances in the Far East, Middle East, Latin America, North Africa and East Europe.
		Today, several Lundbeck subsidiaries in different countries are coming "on BOARD," after having seen the added value provided by projects deployed with BOARD M.I.T. in Lundbeck France.
	www.dmreview.com /article_sub.cfm?articleId=7027 (800 words)

	Lundbeck and Merck & Co enter alliance
		The two pharmaceutical companies have agreed to collaborate on development and commercialisation of the Lundbeck compound gaboxadol in the US Pharmaceutical companies Lundbeck and Merck and Co have entered an agreement to develop and commercialise Lundbeck's sleep disorder drug gaboxadol in the US.
		The drug is currently in phase III clinical trials and the two companies will jointly complete the ongoing programme with Merck funding the majority of the development activities.
		Lundbeck will receive an initial payment of DKK 411 million (USD 70 million) and up to DKK 1.2 billion (USD 200 million) in additional milestone payments.
	www.investindk.com /visNyhed.asp?artikelID=10598 (241 words)

	Lundbeck Looks Ever More Likely To Win Case \| newratings.com (Site not responding. Last check: 2007-11-03)
		1004 GMT [Dow Jones] Lundbeck (LUN.KO) looks like it's got all the cards to win the court case against generic drug makers that are challenging its patent on Lexapro, Jyske Bank says.
		It's been following the trial and says that while it previously gave Lundbeck a 70% chance of winning, it now thinks the likelihood is greater, though it doesn't give a number.
		Notes, however, that ahead of the judge's decision, expected in June, buying Lundbeck is risky.
	www.newratings.com /analyst_news/article_1239130.html (261 words)

Try your search on: Qwika (all wikis)